Free public records show Upjohn in 2 of the markets we cover. It is not a key player in our research.
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
Source: Wikidata, Company record Q16266700. Retrieved 13 Nov 2026.
12 approvals with a product on the US market
Source: Drugs@FDA, Approvals (NDA, ANDA, BLA) held, with a product sold now; newest shown. Retrieved 13 Nov 2026.
Markets we cover where free public records show Upjohn: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
The topics of the markets Upjohn is in.
Stories on the topics Upjohn works in.
About 321,000 people were diagnosed with brain and nervous system tumours in 2022, and about 248,000 died…
Read
More than half of deaths in low- and middle-income countries come from conditions emergency care could treat…
Read
57 million people live with dementia. In May 2025 the US FDA cleared the first blood test used to help…
Read